The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients

被引：0
|
作者：
L. Mast
M. Y. M. Peeters
M. Söhne
C. M. Hackeng
C. A. J. Knibbe
M. P. H. van den Broek
机构：
[1] Department of Clinical Pharmacy,Department of Clinical Pharmacy
[2] Zaandam Medical Centre,Department of Hematology
[3] St. Antonius Hospital,Department of Clinical Chemistry
[4] St. Antonius Hospital,Division of Systems Biomedicine & Pharmacology
[5] St. Antonius Hospital,Department of Pharmaceutical Sciences
[6] Leiden Academic Centre for Drug Research,undefined
[7] Leiden University,undefined
[8] Utrecht University,undefined
来源：
European Journal of Clinical Pharmacology | 2023年 / 79卷
关键词：
LMWH; Nadroparin; Anti-Xa; Renal impairment; Obesity; Dose reduction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1537 / 1547
页数：10
相关论文
共 50 条
  • [1] The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients
    Mast, L.
    Peeters, M. Y. M.
    Soehne, M.
    Hackeng, C. M.
    Knibbe, C. A. J.
    van den Broek, M. P. H.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (11) : 1537 - 1547
  • [2] Prevalence of correct anti-Xa levels in renally impaired patients who are on therapeutic nadroparin
    Smit, Reinier
    van Marum, Rob J.
    Pequeriaux, Nathalie C.
    Hollander, Daan A.
    Bleeker, Michiel W. P.
    Latify, Yasamin
    Hermens, Walter A.
    Derijks, Hieronymus J.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (01) : 139 - 140
  • [3] Prevalence of correct anti-Xa levels in renally impaired patients who are on therapeutic nadroparin
    Reinier Smit
    Rob J. van Marum
    Nathalie C. Péquériaux
    Daan A. Hollander
    Michiel W. P. Bleeker
    Yasamin Latify
    Walter A. Hermens
    Hieronymus J. Derijks
    [J]. European Journal of Clinical Pharmacology, 2018, 74 : 139 - 140
  • [4] Evaluation of Target Peak Anti-Xa Levels in Obese Patients Receiving Prophylactic Enoxaparin
    Marotto, Gina
    Namba, Jennifer
    Auger, William
    Tran, Vy
    [J]. CRITICAL CARE MEDICINE, 2013, 41 (12)
  • [5] NO ACCUMULATION OF A HIGH PROPHYLACTIC NADROPARIN DOSAGE IN PATIENTS WITH MODERATE RENAL INSUFFICIENCY ASSESSED BY PEAK ANTI-XA ACTIVITY
    Atiq, F.
    van den Bemt, P. M. L. A.
    Leebeek, F. W. G.
    van Gelder, T.
    Versmissen, J.
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (08) : E81 - E81
  • [6] Comparison of Anti-Xa Levels in Obese and Non-Obese Pediatric Patients Receiving Treatment Doses of Enoxaparin
    Richard, Ashley A.
    Kim, Shelly
    Moffett, Brady S.
    Bomgaars, Lisa
    Mahoney, Donald, Jr.
    Yee, Donald L.
    [J]. JOURNAL OF PEDIATRICS, 2013, 162 (02): : 293 - 296
  • [7] Monitoring of Anti-Xa in Pregnant Patients with Mechanical Prosthetic Valves Receiving Low Molecular Weight Heparin: Peak or Trough Levels?
    John, Fan
    Goland, Sorel
    Khatri, Nudrat
    Elkayam, Uri
    [J]. CIRCULATION, 2010, 122 (21)
  • [8] Risk Stratification for Supratherapeutic Peak Anti-Xa Levels in Adult Patients on Therapeutic Enoxaparin
    Sheredy, Shane A.
    Stone, Andrew C.
    Mostafavifar, Ahmad M.
    Mostafavifar, Lisa G.
    Smith, Rachel M.
    Doepker, Bruce A.
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (04) : 366 - 374
  • [9] Implications of Manufacturer-Recommended Treatment Doses of Enoxaparin: Evaluation of Achieving Initial Therapeutic Anti-Xa Levels in Patients with Moderate Renal Impairment
    Kang, Young
    White, Beth
    Surti, Palak
    Bentley, Leah
    Jennings, Heath
    Anderson, Irsk
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S166 - S166
  • [10] The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients
    Schijns, W.
    Deenen, M. J.
    Aarts, E. O.
    Homan, J.
    Janssen, I. M. C.
    Berends, F. J.
    Kaasjager, K. A. H.
    [J]. OBESITY SURGERY, 2018, 28 (07) : 1997 - 2005
12345